Welcome to our dedicated page for RESMED SEC filings (Ticker: RSMDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on RESMED's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into RESMED's regulatory disclosures and financial reporting.
ResMed Inc (RMD) is the issuer for a Rule 144 notice filed for planned sales by director Peter C. Farrell. The notice covers an intended sale of 970 shares of common stock, with Merrill Lynch listed as broker, following earlier Rule 144-reportable sales in the prior three months.
ResMed Inc. (RMD) announced that it entered into an accelerated share repurchase (ASR) agreement with Citibank, N.A. to repurchase $450.0 million of its common stock. The ASR is conducted under a board-approved repurchase authorization for 20,000,000 shares of common stock originally approved in February 2014.
ResMed intends to fund the ASR using proceeds from the sale of its MatrixCare business and cash on hand. On September 3, 2026, ResMed will pay Citibank $450.0 million and expects an initial delivery of shares equal to 80% of $450.0 million divided by the closing price of its common stock on September 2, 2026. The final number of shares repurchased will be determined based on the average daily volume weighted average price of the stock during the ASR term, less a discount and subject to adjustments. Final settlement is scheduled for December 2026, although Citibank may elect to complete it earlier under the agreement’s terms.
ResMed Inc. reported board and auditor changes. On August 13, 2026, the Audit Committee dismissed KPMG as independent registered public accounting firm and selected PricewaterhouseCoopers LLP (PwC), subject to completion of PwC’s standard client acceptance procedures, for the fiscal year ending June 30, 2027. KPMG’s audit reports for the fiscal years ended June 30, 2026 and 2025 contained no adverse opinions, disclaimers, or qualifications, and ResMed states there were no disagreements or reportable events with KPMG. The company also states it did not consult PwC on accounting or auditing matters during these periods. Director Ronald Taylor informed the Board he will not stand for election at the 2026 annual meeting, expected on November 18, 2026, and will retire at that time. The Board approved Carol Burt as lead director effective November 15, 2026, and these governance changes were announced in a press release furnished as an exhibit.
ResMed Inc. is a Delaware-based global leader in digital health and cloud‑connected medical devices focused on sleep and breathing disorders and residential care software. Operations are organized into two segments: Sleep and Breathing Health, and Residential Care Software.
The company sells CPAP, APAP, bilevel and ventilation devices, masks, diagnostics, and AI‑enabled software such as AirView and myAir in more than 140 countries, employing approximately 11,370 people. Devices generated about 51% of net revenue in fiscal 2026, masks and diagnostics about 37%, and Residential Care Software about 12%.
In 2025 ResMed acquired VirtuOx, an independent diagnostic testing facility, expanding home‑based diagnostics. In June 2026 it acquired Noctrix Health, adding an FDA De Novo classified wearable device for restless legs syndrome. On June 30, 2026, ResMed entered a definitive agreement to sell its MatrixCare business for $490 million in cash, sharpening focus on core sleep, breathing, and connected home‑based healthcare.
ResMed Inc. Chairman and CEO Michael J. Farrell exercised 4,991 options for ResMed Common Stock at an exercise price of $146.34 per share and acquired the same number of shares on August 7, 2026. He then sold 4,991 shares of ResMed Common Stock at a weighted average price of $205.6895 per share, with individual trades ranging from $202.410 to $204.160. The option exercise and related sale were conducted under a Rule 10b5-1 plan adopted October 31, 2024. Following the option transaction, he held 14,975 ResMed Common Stock options and had an indirect holding of 2,090 ResMed Common Stock shares through the Lisette and Michael Farrell Family Trust.
AustralianSuper Pty Ltd reported a significant ownership position in ResMed Inc. The investor beneficially owns 8,276,381 ordinary shares of ResMed Inc., representing 5.71% of the class as of June 30, 2026. AustralianSuper has sole power to vote and dispose of all 8,276,381 shares, with no shared voting or dispositive power reported. The filing identifies AustralianSuper as an Australian entity operating as an employee benefit plan and/or investment company, disclosing this stake on a passive Schedule 13G basis.
ResMed shareholder Michael Farrell lists a proposed sale of 4,991 shares of common stock, to be sold for cash on 08/07/2026 through Fidelity Brokerage Services LLC on the NYSE, in connection with a stock option exercise.
The disclosure also lists prior sales of 4,991 shares of common stock on each of 05/07/2026, 06/08/2026, and 07/07/2026, with aggregate sale prices of $1,037,232.61, $968,064.34, and $1,090,770.57, respectively.
ResMed Inc. reported higher sales and earnings for the quarter and fiscal year ended June 30, 2026, and announced a larger dividend. For the fourth quarter, revenue was $1,464 million, up 9% from $1,348 million. GAAP diluted EPS was $2.64 versus $2.58, while non-GAAP diluted EPS rose to $2.95 from $2.55. GAAP gross margin declined to 58.8% from 60.8%, reflecting items such as $41.9 million of Astral field safety notification expenses, but non-GAAP gross margin improved to 62.3% from 61.4%.
For fiscal 2026, revenue reached $5,653 million, a 10% increase year over year. GAAP diluted EPS was $10.43 versus $9.51, and non-GAAP diluted EPS increased to $11.17 from $9.55, as operating margin expanded to 33.4% and non-GAAP operating margin to 36.1%. Operating cash flow for the year was $1,806 million. The board declared a quarterly cash dividend of $0.66 per share, a 10% increase, with a record date of August 20, 2026 and payment on September 24, 2026; holders of CHESS Depositary Interests on the ASX will receive an equivalent amount based on the 10:1 CDI-to-share ratio.
ResMed Inc. director Peter C. Farrell reported selling 8,000 shares of ResMed Common Stock on 2026-08-05 at $225.00 per share in an open-market or private transaction. The sale was conducted under a Rule 10b5-1 plan adopted August 12, 2025.
After this transaction, Farrell directly holds 52,773 shares of ResMed Common Stock.
A Form 144 related to RMD reports a proposed sale of up to 8,000 common shares through Merrill Lynch on the NYSE, with an indicated value of $1,799,642.92. Shares outstanding are listed as 145,056,384. The filing also lists multiple stock options for Peter C Farrell with various grant and exercise dates and share amounts.